Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_assertion type Assertion NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_head.
- NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_assertion description "[Clinical trials using new agents targeting genetic alterations (driver mutations) in lung cancer have demonstrated significant improvements in patient outcomes (for example, gefitinib, erlotinib or crizotinib for lung adenocarcinomas harboring EGFR mutations or EML4-ALK fusions, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_provenance.
- NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_assertion evidence source_evidence_literature NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_provenance.
- NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_assertion SIO_000772 25626064 NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_provenance.
- NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_assertion wasDerivedFrom befree-2016 NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_provenance.
- NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_assertion wasGeneratedBy ECO_0000203 NP1258863.RArbyAOI3hXBIOUlY_ihs4PB4E14CiYeCDkGKk5_U-Pl4130_provenance.